In the News
Penn State Hershey and Serametrix to seek companion diagnostic for immunotherapy in pediatric cancers
OncoSec and Serametrix Collaborate to Identify Potential Biomarkers to Enhance Skin Cancer Immune Therapies
November 16, 2011
SAN DIEGO, CA, -- OncoSec Medical Incorporated (OTCBB: ONCS), which is developing its advanced-stage OMS ElectroOncology therapies to treat solid tumor cancers, today announced it has entered into a collaborative research agreement with Serametrix Corporation to analyze subjects in three OncoSec Phase II clinical trials treating melanoma, Merkel cell carcinoma and cutaneous Tcell lymphoma with the goal of identifying biomarkers that may refine and enhance the selection of patients potentially responsive to these treatments. Terms of the final agreement have not been released.
Serametrix launches test for measuring serum antibodies to leading cancer antigen NY-ESO-1
April 15, 2010
SAN DIEGO--(BUSINESS WIRE)--Serametrix has announced the commercial launch of a serum test for measuring serum antibodies to the important tumor antigen NY-ESO-1. The test will be offered as a service to drug companies and clinicians for correlative studies, monitoring and potentially predicting patient responses to cancer treatments. The announcement follows last year’s partnership and licensing agreement between Serametrix and the Ludwig Institute for Cancer Research in New York.
Serametrix partners with the Ludwig Institute for Cancer Research to develop and commercialize serum-based diagnostics
October 14, 2009
SAN DIEGO--(BUSINESS WIRE)--Serametrix Corporation, a personalized medicine company, today announced their partnership with the Ludwig Institute for Cancer Research Ltd. (LICR). The agreement will combine LICR’s historic discoveries in tumor immunology with the technologies and commercial capabilities of Serametrix.
Dan Chambers Joins Serametrix as Chief Intellectual Property Counsel
August 3, 2009
Serametrix today announced the addition of Dan Chambers to its management team as Chief Intellectual Property Counsel. "Since its inception Serametrix has been successfully building valuable datasets of diagnostic and prognostic biomarker panels"
Serametrix announces launch of Seromic™ product line
May 28, 2009
Serametrix Corporation has today launched a new range of serum profiling assays, significantly expanding the current assay offering. Following the success of the Cancer Testis (CT) antigen assay a new range of disease-specific services will comprise the Seromic™ product line.